Abbott Shares Drop Despite Strong Q2 Earnings and Medical Device Demand
Abbott Laboratories' stock fell nearly 6% after lowering its 2025 sales outlook following a mixed Q2 report, despite beating revenue and earnings estimates; growth in medical devices and established pharmaceuticals was strong, but diagnostics underperformed, leading to a cautious outlook and a premarket decline.